Timothy A. Chan MD, PhD is a physician-scientist, staff, professor, and attending physician at the Cleveland Clinic and Case Comprehensive Cancer Center. He is Chair and Founding Director of the Center for Immunotherapy and Precision Immuno-Oncology at the Cleveland Clinic, which focuses on immunotherapy research and developmental therapeutics. He is PI of a cancer genetics laboratory and is an expert in cancer biology and immunogenomics.
Dr. Chan is an NCI Outstanding Investigator and an elected member of the American Association of Physicians (AAP). He has over 200 publications in journals including Nature, Science, The New England Journal of Medicine, Cell, and others. He is on the scientific advisory board for Cell and the Frederick National Laboratory/National Cancer Institute. He received an MD, a PhD in cancer genetics, completed a residency in radiation oncology, and a fellowship at the Johns Hopkins School of Medicine.
The focus of the Chan laboratory is to understand the genomic basis of tumor development and treatment response. We use both large-scale genomic analyses and functional dissection to determine what drives oncogenesis. From this information, we seek to develop improved diagnostic and therapeutic modalities for human cancers.
The Chan laboratory specializes in using genomic analysis to characterize the drivers of genetic programs underlying immunotherapy and oncogenesis. These approaches include large-scale analyses, functional genomics, immunogenomics, biochemical and molecular analyses, and mouse modeling. The lab has a special interest in deciphering the mechanisms underlying immunotherapy treatment response, resistance, and mechanisms.